HF prevalence and evolution of HF in DM II patients at high risk - HF-LanDMark

Study identifier:D1843R00313

ClinicalTrials.gov identifier:NCT04482283

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Epidemiological 2-year prospective study to estimate the prevalence and evolution of Heart Failure and identify potential predictors for the development of symptomatic HF in patients withT2 Diabetes Mellitus at high CV risk

Medical condition

RELATED REGISTRY SEARCH

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

244

Study type

Observational

Age

40 Years - 80 Years

Date

Study Start Date: 20 Jul 2020
Estimated Primary Completion Date: 30 Nov 2024
Estimated Study Completion Date: 30 Nov 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria